Silverarc Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Silverarc Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-51,245	Closed	-$6.4M	–	79
2024 Q3	$6.4M	Buy	51,245 +9,245	+22%	+$1.28M	1.44%	23
2024 Q2	$6.64M	Buy	+42,000	New	+$5.4M	1.57%	21
2024 Q1	–	Sell	-46,884	Closed	-$4.52M	–	96
2023 Q4	$4.52M	Buy	46,884 +37,687	+410%	+$3.62M	1.35%	33
2023 Q3	$1.11M	Sell	9,197 -20,663	-69%	-$2.34M	0.34%	57
2023 Q2	$3.42M	Buy	29,860 +20,590	+222%	+$2.66M	1.06%	32
2023 Q1	$1.28M	Buy	+9,270	New	+$1.2M	0.53%	55

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Silverarc Capital Management's SRPT Position: Q4 2024 in Review

Silverarc Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 51,245 shares — an estimated $6.4M sold.

Silverarc Capital Management first reported a position in SRPT in Q1 2023 and held it in 6 quarters. The position peaked at $6.64M in Q2 2024. 465 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

Silverarc Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
Silverarc Capital Management sold 51,245 Sarepta Therapeutics shares in Q4 2024, an estimated $6.4M.
Silverarc Capital Management first reported a position in Sarepta Therapeutics in Q1 2023 and held it in 6 quarters.
Silverarc Capital Management's Sarepta Therapeutics position peaked at $6.64M in Q2 2024.
465 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Silverarc Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.